SVB Leerink starts Immunic at OP, PT $45

SVB Leerink launched coverage of Immunic (NASDAQ:IMUX) with an “outperform” rating and $45 price target. The stock closed at $18.87 on Oct. 1.

Immunic is focused on development of novel therapeutics for the treatment of multiple chronic inflammatory and autoimmune diseases. 

The company’s lead asset is IMU-838, a selective, orally available second-generation dihydroorotate dehydrogenaseinhibitor that recently achieved positive top-line results in a Phase 2b trial in relapsing-remitting multiple sclerosis. It is also being studied in a range of additional autoimmune indications, with Phase 2 trials ongoing in ulcerative colitis, COVID-19, and primary sclerosing cholangitis, writes analyst Thomas Smith. 

“We see IMU-838 as a partially de-risked asset in relapsing-remitting multiple sclerosis, with prior regulatory approval and commercial success for Sanofi’s Aubagio (teriflunomide) providing clinical and commercial validation for the target, and Immunic’s Phase 2b results suggesting a potentially differentiated profile,” he said. 

“While we expect IMU-838 may face some commercial headwinds in multiple sclerosis, including multiple generic oral entrants, we see significant commercial opportunity in ulcerative colitis and Crohn disease,where IMU-838 may be first-in-class with oral administration and a differentiated clinical profile,” he added. 

Mr. Smith said his model excludes revenues for COVID-19 or primary sclerosing cholangitis, although “near-term data readouts could establish proof-of-concept in these indications driving upside to our current Immunic forecasts.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.